APM
NASDAQ · Biotechnology
Aptorum Group Ltd-Class A
$9.58
+0.60 (+6.68%)
Open$8.83
Previous Close$8.98
Day High$9.60
Day Low$8.45
52W High$44.70
52W Low$6.00
Volume—
Avg Volume310.0K
Market Cap5.70M
P/E Ratio—
EPS$-0.35
SectorBiotechnology
Analyst Ratings
Strong Buy
6 analysts
Price Target
+29.3% upside
Current
$9.58
$9.58
Target
$12.39
$12.39
$9.33
$12.39 avg
$15.15
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 3.16M | 3.05M | 3.43M |
| Net Income | -41,291 | -50,098 | -44,694 |
| Profit Margin | -1.3% | -1.6% | -1.3% |
| EBITDA | -71,807 | -61,818 | -76,890 |
| Free Cash Flow | -34,920 | -36,621 | -42,296 |
| Rev Growth | +21.0% | -5.0% | +24.8% |
| Debt/Equity | 0.35 | 0.39 | 0.35 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.68 | -0.45% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $412.84 | -1.20% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $138.12 | -0.01% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $508.33 | -1.57% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $803.64 | -0.29% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $227.29 | +0.07% | 35.2 | 28.41B |